BioVaxys Executes Letter of Intent for Major Immunotherapeutics Technology Acquisition ...Middle East

PR Newswire - News
BioVaxys Executes Letter of Intent for Major Immunotherapeutics Technology Acquisition
VANCOUVER, BC, Dec. 22, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that it has executed a non-binding Letter of Intent ("LOI") to acquire the core platform technology and entire immunotherapeutics...

Hence then, the article about biovaxys executes letter of intent for major immunotherapeutics technology acquisition was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BioVaxys Executes Letter of Intent for Major Immunotherapeutics Technology Acquisition )

Apple Storegoogle play

Last updated :

Also on site :